Axonis Therapeutics, a pioneering Boston-based neuro-focused biotechnology company, has successfully raised an impressive $115 million in its latest funding round. This substantial investment underscores Axonis' commitment to transforming the landscape of neurological treatments through innovative research and development. The company specializes in creating first- and best-in-class medications aimed at KCC2, a vital mediator of inhibitory processes in the brain, and is at the forefront of translating groundbreaking discoveries from prestigious institutions like Boston Children’s Hospital, Harvard University, and Laval University into viable therapeutic options.
As a proud member of the venBio portfolio, Axonis has previously secured over $34 million in dilutive Seed funding along with more than $8 million in competitive non-dilutive grants and awards, all directed towards their mission of enhancing the quality of life for individuals affected by neurological disorders. The newly acquired capital will bolster Axonis' ongoing efforts to advance its drug development programs, particularly as it gears up for the initiation of first-in-human trials in 2024 for their flagship oral KCC2 potentiator drug, AXN-027. This revolutionary drug aims to finely tune inhibition in the central nervous system, offering promise for treating conditions such as epilepsy, chronic pain, and other complex CNS pathologies. With a team of leading drug hunters and target biology experts driving their proprietary KCC2 discovery engine, Axonis Therapeutics is poised to make significant strides in the biotechnology industry, with the potential to establish itself as a leader in this promising and transformative drug space.
.png&w=3840&q=75)
